Anonymous
Guest
Anonymous
Guest
Decades ago cancer immunotherapy was considered by some to be voodoo medicine. "Initial studies were not very effective, and many doctors thought it was a lot of hype with very few results," says James Gulley, MD, PhD, director of the clinical immunotherapy group at the National Cancer Institute (NCI). All that began to change in 2010, when the FDA approved the cancer vaccine Provenge to treat metastatic prostate cancer. The results from the clinical trials on Provenge were remarkable, giving patients an extra four months, on average, to live. And they didn't just live longer; they felt better, too. The findings were early proof that the body's own immune system could be a powerful weapon against cancer. Today potentially more effective and longer-lasting vaccine immunotherapies are being tested in more than 600 clinical trials as treatments for many of the deadliest cancers, including those of the ovaries, lungs, and breast.
Read more: http://www.oprah.com/health/Provenge-Cancer-Vaccine/1#ixzz2cdbIc500
Word is spreading big time.
Read more: http://www.oprah.com/health/Provenge-Cancer-Vaccine/1#ixzz2cdbIc500
Word is spreading big time.